Pure Global
NCT06301854

Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients With Erectile Dysfunction
Vigonvita Life Sciences·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Erectile Dysfunction
Drug/Device/Intervention
TPN171H
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vigonvita Life Sciences
Location
Hefei,Beijing,Beijing,Guangzhou,Guangzhou,Guangzhou,Shantou,Shantou,Shenzhen,Guilin,Guiyang,Qingyuan,Shijiazhuang,Xingtai,Zhengzhou,Zhengzhou,Wuhan,Wuhan,Changsha,Loudi,Yueyang,Suzhou,Nanchang,Yichang, China
Timeline & enrollment
Phase
Phase 3
Start date
Apr 12, 2024
End date
Apr 30, 2025
Enrollment
400 participants
Primary outcome

Incidence of adverse events (AE) and adverse drug reactions (ADRs) during treatment observation.

Summary

This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in
 men with erectile dysfunction.

ICD-10 classifications
Orgasmic dysfunctionOther disorders of penisOther specified disorders of penisSexual dysfunction, not caused by organic disorder or diseaseTesticular dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06301854
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06301854 through Pure Global AI's free database. This Phase 3 trial is sponsored by Vigonvita Life Sciences and is currently Recruiting. The study focuses on Erectile Dysfunction. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.